[Inhibitory effect of recombinant human endostatin on angiogenesis and lung metastasis of mouse lung adenocarcinoma LA795].
OBJECTIVE
To study the inhibitory effect of recombinant human endostatin (rhES) on the angiogenesis and lung metastasis of mouse lung adenocarcinoma LA795.


METHODS
The recombinant yeast strain containing the gene sequence encoding highly soluble rhES was induced by methanol for rhES production, which was purified with heparin affinity chromatography. T739 mice with subcutaneous inoculation of LA795 cells were randomized into 2 groups (10 in each group) to receive injection of either rhES (20 mg/kg x b x w x per day) or PBS in the same volume for 14 consecutive days starting from the sixth day after the inoculation. The angiogenesis and lung metastasis of the implanted tumors were subsequently observed.


RESULTS
Purified rhES was successfully obtained. As shown by immunohistochemistry, the tumors in the mice receiving rhES treatment exhibited less density of the microvessels than those in the PBS-treated mice did (P<0.01). Pathological examination of the lung tissue of the mice in rhES group found no visible signs of tumor metastasis, which, in contrast, was widespread in PBS group. The weight of the lungs was also significantly different (P<0.01).


CONCLUSIONS
rhES possesses good biological properties and can potently inhibit the angiogenesis and lung metastasis of mouse lung adenocarcinoma LA795.
Xia
Hu
H
Department of Respiratory Diseases, Zhujiang Hospital, First Military Medical University, Guangzhou 510282, China.
Luo
Li-min
LM
Fan
Ying-fang
YF
Tong
Wan-cheng
WC
Wen
Jin-xu
JX
D000230:Adenocarcinoma / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D003094:Collagen / Q000627:therapeutic use*; D043169:Endostatins; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000098:blood supply / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D051379:Mice; D010446:Peptide Fragments / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D043169:Endostatins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D003094:Collagen